Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer
Click the "View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
• Introduce improved models for early and effective biomarker testing
• Identify appropriate patients and optimize treatment for RET targeted therapy
• Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Director, Cancer Services
Vice Chair, Hematology and Medical Oncology
Co-Director Community Based Clinical Trials
Sidney Kimmel Cancer Center - Jefferson Health
Marcia Browse, MD, PhD, FASCO
Consultant: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly
Research Support: Bayer, Blueprint Medicines, Eisai Co., Ltd., Exelixis, Inc., Lilly, Loxo Oncology/Lilly